<DOC>
	<DOCNO>NCT02037555</DOCNO>
	<brief_summary>This prospective , multicenter , randomize , double-blind , placebo-controlled study . The purpose study determine safety effectiveness human-derived antithrombin III ( AT-III [ Human ] ) supplementation prior high-risk , non-emergency , cardiac surgery cardiopulmonary bypass ( CPB ) . A total 404 adult subject undergo CPB meet study eligibility criterion randomize receive either AT-III ( Human ) placebo .</brief_summary>
	<brief_title>Safety Efficacy Preoperative Antithrombin Supplementation Patients Undergoing High-Risk Cardiopulmonary Bypass</brief_title>
	<detailed_description />
	<mesh_term>Antithrombins</mesh_term>
	<mesh_term>Antithrombin III</mesh_term>
	<criteria>Subject need nonemergency cardiac surgery cardiopulmonary bypass . Types cardiac operation permit : 1 . Complex/combined procedure ( coronary artery bypass graft [ CABG ] plus valve ) , double/triple valve repair/replacements , ascend aorta/aortic arch surgery ( without baseline AT level restriction preoperative heparin requirement ) . OR 2 . Isolated CABG single valve repair/replacements allow either ( ) AT level le 80 % OR ( b ) preoperative heparin receive ( unfractionated heparin [ UFH ] least 12 hour ; low molecularweight heparin [ LMWH ] 5 day ) . Subject need emergency surgery . Subject need heart transplantation . Use minimally invasive surgery . Previous cardiac operation . Infective endocarditis . Thromboembolic event , stroke , STelevated myocardial infarction within 7 day surgery . Cardiogenic shock time surgery . Renal dysfunction : Creatinine level &gt; 2 mg/dL chronic dialysis . Liver dysfunction : aspartate transaminase , alanine aminotransferase increase ≥2fold upperlimit local lab normal range . Treatment Clopidogrel Ticagrelor within 5 day surgery , Prasugrel within 7 day surgery , glycoprotein IIb/IIIa receptor blocker within 24 hour surgery . Treatment new oral anticoagulant ( Apixaban , Rivaroxaban , Dabigatran ) within 48 hour surgery . Vitamin K antagonist therapy international normalized ratio &gt; 1.3 day surgery . Platelet count &lt; 120,000/μL . History suspicion congenital acquire coagulation disorder . History anaphylactic reaction ( ) blood blood component . Allergies excipients study drug . Refusal receive allogenic transfusion bloodderived product . Received AT treatment within last 3 month prior Screening visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Antithrombin</keyword>
	<keyword>Cardiopulmonary bypass</keyword>
</DOC>